Conclusion of a Research Collaboration and License Option Agreement with a U.S. Public Pharmaceutical Company

Current report no. 54/2025

Drafting date: 17.11.2025

Subject: Conclusion of a Research Collaboration and License Option Agreement with a U.S. Public Pharmaceutical Company

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A. (the "Company", "Captor") hereby announces the conclusion of a research and evaluation agreement (the "Agreement") with a U.S. public pharmaceutical company (the "Partner").

Under the terms of the Agreement, Captor will grant the Partner a paid, time-limited exclusivity to conduct research on the Company's proprietary NEK7 protein degraders in the Partner's animal disease models.

Upon obtaining satisfactory research results, the Partner will have an option to enter into an exclusive license agreement. This license would cover the further development and commercialization of a selected NEK7 degrader within a specific, defined therapeutic area.

According to the terms of the potential license agreement, Captor may be entitled to:

1. Receive an upfront payment in the amount of a "mid single digit million USD".

2. Receive development and commercial milestone payments totaling up to a "triple-digit million USD".

3. Receive royalties on future net sales of products based on the license.

Simultaneously, the Company will retain full rights to the further development and commercialization of NEK7 degraders in all indications and therapeutic areas outside the scope of the Partner's license.

Due to the strategic nature of the collaboration, the Partner's name and the specific financial terms of the Agreement are subject to a confidentiality clause.